7-羟基-6-甲氧基-3,4-二氢异喹啉 | 4602-73-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 异喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氢异喹啉
• 中文名称: 7-羟基-6-甲氧基-3,4-二氢异喹啉
• 中文别名: 3,4-二氢-7-羟基-6-甲氧基异喹啉；6-甲氧基-7-羟基-3,4-二氢异喹啉
• 英文名称: 7-hydroxy-6-methoxy-3,4-dihydroisoquinoline
• 英文别名: 6-Methoxy-7-hydroxy-3,4-dihydro-isochinolin；6-methoxy-3,4-dihydroisoquinolin-7-ol
• CAS: 4602-73-7
• 化学式: C₁₀H₁₁NO₂
• mdl: MFCD00143517
• 分子量: 177.203
• InChiKey: UQBWYWCIBNWMPI-UHFFFAOYSA-N

物化性质

• 熔点：
  187-191 °C
• 沸点：
  356.0±42.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）
• 稳定性/保质期：
  在常温常压下保持稳定，应避免与不相容的材料接触。

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  41.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R21/22,R36/38
• 海关编码：
  29335995
• WGK Germany：
  3
• RTECS号：
  YQ8750000
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Name:	7-Hydroxy-6-methoxy-3 4-dihydroisoquinoline 98% Material Safety Data Sheet
Synonym:	7-Isoquinolinol, 3,4-dihydro-6-methoxy-; 3,4-Dihydro-7-hydroxy-6-methoxyisoquinoline
CAS:	4602-73-7

Section 1 - Chemical Product MSDS Name:7-Hydroxy-6-methoxy-3 4-dihydroisoquinoline 98% Material Safety Data Sheet
Synonym:7-Isoquinolinol, 3,4-dihydro-6-methoxy-; 3,4-Dihydro-7-hydroxy-6-methoxyisoquinoline

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
4602-73-7	7-Hydroxy-6-methoxy-3,4-dihydroisoquin	98	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical aid immediately. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. Dusts at sufficient concentrations can form explosive mixtures with air. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Keep container closed when not in use.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Exposure Limits CAS# 4602-73-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 193.00 - 195.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: soluble in hot water
Specific Gravity/Density:
Molecular Formula: C10H11NO2
Molecular Weight: 177.20

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 4602-73-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
7-Hydroxy-6-methoxy-3,4-dihydroisoquinoline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 4602-73-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 4602-73-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 4602-73-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-羟基-6-甲氧基-3,4-二氢异喹啉 在 盐酸 、 sodium tetrahydroborate 、 Amberlite IRA 410 (Cl- form) 作用下， 以 甲醇 为溶剂， 反应 24.0h， 生成 紫堇杷灵碱
  参考文献：
  名称：

  小檗悬浮培养物中网状番荔枝碱的降解

  摘要：

  摘要 用 13 C 标记的网状番荔枝碱在体内对匍匐茎芽孢杆菌细胞悬浮培养物进行 13 C NMR 分析。观察到细胞中富含 13 C 的原小檗碱生物碱，并检测到网状番荔枝碱生物降解为简单的异喹啉生物碱 pycnarrhine。使用标记的苄基异喹啉和其他植物物种的细胞悬浮培养物探索了降解的范围和机制。

  DOI：

  10.1016/0031-9422(90)89026-6
• 作为产物：
  描述：

  6,7-二甲氧基-3,4-二氢异喹啉 在 氢溴酸 作用下， 生成 7-羟基-6-甲氧基-3,4-二氢异喹啉
  参考文献：
  名称：

  3-（苯乙氨基）脱甲基（氧）aptaptamine作为抗休眠的分枝杆菌物质：分离，评估和全合成。

  摘要：

  从Aaptos sp。的海洋海绵中重新发现了3-（苯乙氨基）脱甲基（氧）aptapamine（1）。通过生物测定指导的分离，作为一种抗休眠的分枝杆菌物质。化合物1在有氧条件和缺氧条件下（都处于休眠状态）均显示出对牛分枝杆菌BCG的有效抑菌活性，最低抑菌浓度为0.75 µg / mL。化合物1还有效对抗致病性结核分枝杆菌菌株，包括临床耐多药菌株。此外，成功地合成了1及其类似物3-氨基脱甲基（氧基）Aaptamine（2）有足够的数量用于进一步的生物学研究。

  DOI：

  10.1016/j.tetlet.2020.151924

文献信息

• Multicomponent Synthesis of Tetrahydroisoquinolines
  作者：Linwei Zeng、Bo Huang、Yangyong Shen、Sunliang Cui

  DOI：10.1021/acs.orglett.8b01159

  日期：2018.6.15

  A multicomponent synthesis of tetrahydroisoquinolines from carboxylic acids, alkynyl ethers, and dihydroisoquinolines is described. This process features readily available starting materials, simple experimental procedures for achievement of molecule complexity, and structural diversity. The preliminary control experiment and crossover reaction provide important insight into the reaction mechanism

  描述了由羧酸，炔基醚和二氢异喹啉多组分合成四氢异喹啉。该过程的特点是容易获得的起始原料，实现分子复杂性的简单实验程序以及结构的多样性。初步控制实验和交叉反应为反应机理提供了重要的认识。可以将形成的四氢异喹啉转化为一系列化合物。
• Direct Synthesis of Dihydropyrrolo[2,1‐ <i>a</i> ]Isoquinolines through FeCl ₃ Promoted Oxidative Aromatization
  作者：Hai‐Lei Cui、Lu Jiang、Hao Tan、Si Liu

  DOI：10.1002/adsc.201900756

  日期：2019.10.22

  We have developed a straightforward FeCl3 promoted synthesis of dihydropyrrolo[2,1‐a]isoquinolines through formal (3+2) cycloaddition/oxidative aromatization cascade of dihydroisoquinoline with Morita‐Baylis‐Hillman carbonates (up to 96% yield). Further modifications of the obtained products were successful through simple chemical transformations providing a diverse range of natural product‐like molecules

  我们已经开发出一种简单的FeCl 3促进的二氢吡咯并[2,1- a ]异喹啉的合成，方法是通过二氢异喹啉与Morita-Baylis-Hillman碳酸盐的正式（3 + 2）环加成/氧化芳构化级联（产率高达96％）。通过简单的化学转化成功获得了进一步的修饰产物，提供了多种天然产物样分子（12个例子）。
• 8-Phenylisoquinolines And Pharmaceutical Composition Used In Treatment For Sepsis
  申请人：SU MING-JAI

  公开号：US20130059882A1

  公开（公告）日：2013-03-07

  A compound is provided. The compound includes a formula of:

  一个混合物被提供。该混合物包括一个公式：
• [EN] 8-PHENYL-ISOQUINOLINES AND PHARMACEUTICAL COMPOSITION THEREOF USED IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME<br/>[FR] 8-PHÉNYL-ISOQUINOLINES ET COMPOSITION PHARMACEUTIQUE ASSOCIÉES UTILISÉES DANS LE TRAITEMENT DU SYNDROME DU CÔLON IRRITABLE
  申请人：YU LINDA CHIA HUI

  公开号：WO2018157233A1

  公开（公告）日：2018-09-07

  A series of 8-phenyl-isoquinoline derivatives (I) exhibit high binding affinity to 5-HT7 receptor (5-HT7R) and demonstrate potent antinociceptive activity in two animal models for Irritable Bowel Syndrome (IBS) by intraperitoneal injection (i.p.) or by oral administration (p.o.). These 5-HT7 receptor antagonists are a new class of therapeutic agents for the treatment of IBS.

  一系列8-苯基异喹啉衍生物（I）显示出高结合亲和力，对5-HT7受体（5-HT7R）具有潜在的抗痛觉活性，在两种肠易激综合征（IBS）动物模型中通过腹腔注射（i.p.）或口服（p.o.）显示出强效的抗痛觉活性。这些5-HT7受体拮抗剂是一类新型的治疗剂，用于治疗IBS。
• PHARMACEUTICAL COMPOUNDS
  申请人：Duffield Andrew John

  公开号：US20100087475A1

  公开（公告）日：2010-04-08

  This application describes substituted 1,3,4,6,7,11b-hexahydro-benzo(a)quinolizine compounds, pharmaceutical compositions containing them, processes for making them and their therapeutic methods.

  该应用程序描述了取代的1,3,4,6,7,11b-六氢苯并(a)喹啉化合物，含有它们的药物组合物，制备它们的方法以及它们的治疗方法。